Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Our previous studies showed that non-immunogenic H-2
d
tumor cells of distinct epithelial histotypes can become highly immunogenic, induce a protective CD4
+
T cell response and vaccinate the animals against parental MHC-II-negative cells if they are rendered MHC class II-positive by stable transfection with the Air-1-encoded MHC-II
transcriptional activator
CIITA. These studies did not establish, however, whether tumor immunity was the consequence of a direct priming of naive CD4
+
T lymphocytes by CIITA-driven MHC-II-expressing tumor cells or by MHC-II-tumor antigen complexes engulfed by dendritic cells (DC) and exposed on the surface of these professional antigen presenting cells (APC). In the present investigation, we provide definitive evidence that CIITA-tumor cells are the crucial APC
in vivo
for CD4
+
T cell priming. By using a transgenic H-2
b
mouse model, the CD11c.DTR C57BL/6 mice, in which DC can be functionally deleted by administration of diphteria toxin, we show that CIITA-tumor cells of two distinct histotypes can be rejected or strongly retarded in their growth in DC-deleted mice. To rule out that in absence of DC, other professional APC could prime naive CD4
+
T cells, we deleted the macrophages in CD11c.DTR C57BL/6 mice by administration of liposome
Clodronate
and still obtained rejection or strong retardation in tumor growth of CIITA-tumor cells. Our results challenge the diffuse belief that non-professional APC cannot efficiently prime naive T cells
in vivo.
Moreover, the demonstration of the general validity of our approach in different genetic backgrounds may open a way for new strategies of antitumor treatment in clinical settings.
...
PMID:CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4
+
TH cells
in vivo
and vaccinate the host against parental MHC-II-negative tumor cells. 2819 87
